The Ozempic lawsuit 2026 landscape has reached a critical inflection point. As of June 1, 2026, federal MDL 3094 holds 3,763 pending cases — the highest case count in the litigation’s history — while a brand-new MDL for vision-loss injuries just completed its Science Day on June 2, 2026. A pivotal Daubert ruling has already reshaped the evidentiary battlefield, bellwether trials are on the horizon, and zero global settlements have been announced. For injured patients and legal observers alike, this is the most consequential pharmaceutical mass tort currently in motion.
Where the Ozempic MDL Stands in June 2026: Case Counts and Court Structure
MDL 3094, formally styled In re GLP-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, was established in February 2024 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. What began as a few hundred coordinated claims has exploded into one of the fastest-growing pharmaceutical mass torts in recent memory. According to tracking data from MDLUpdate.com, the case count has grown approximately 130% since January 2025, climbing from roughly 1,000 cases in mid-2024 to 3,763 pending actions as of June 1, 2026.
The defendants named across these thousands of complaints are Novo Nordisk — manufacturer of Ozempic, Wegovy, Rybelsus, and Saxenda — and Eli Lilly, maker of Mounjaro, Zepbound, and Trulicity. Both companies have vigorously contested liability, and no global settlement framework has emerged from either defendant as of this writing. The Judicial Panel on Multidistrict Litigation (JPML) took an additional step by expanding MDL 3094 to include Saxenda cases, though it declined to consolidate blood clot (DVT) injury claims into the same proceeding, leaving that category of injury to be litigated separately.
A second MDL — MDL 3163, addressing NAION (non-arteritic anterior ischemic optic neuropathy) vision-loss injuries — was created in December 2025 by the JPML, also in the Eastern District of Pennsylvania and also assigned to Judge Marston. This dual-MDL structure means Judge Marston is now simultaneously managing two of the most scientifically complex pharmaceutical litigations in the federal court system.
What Injuries Are Being Alleged in the Ozempic Lawsuit 2026
Understanding the injury breakdown is essential context for anyone evaluating the Ozempic lawsuit 2026. Based on a breakdown provided by Novo Nordisk’s attorneys at a January 13, 2026 hearing, the pending complaints in MDL 3094 allege the following categories of harm:
| Injury Category | Share of Complaints | MDL |
|---|---|---|
| Gastroparesis (stomach paralysis) | ~75% | MDL 3094 |
| Ileus (intestinal obstruction) | ~18% | MDL 3094 |
| Gallbladder complications | ~8% | MDL 3094 |
| NAION (vision loss) | Separate MDL | MDL 3163 |
The connection between GLP-1 drugs and these injuries is mechanistic, not incidental. GLP-1 receptor agonists work by delaying gastric emptying to reduce appetite and slow digestion — the same biological action that plaintiffs allege becomes permanently debilitating when the drug causes the stomach to stop emptying food entirely, a condition known as gastroparesis. For individuals assessing the potential value of a gastrointestinal injury claim, a medical malpractice calculator can provide a preliminary estimate of damages based on injury severity, treatment costs, and lost income.
The Landmark Daubert Ruling: What It Means for Gastroparesis Plaintiffs
The single most consequential procedural development in the Ozempic lawsuit 2026 landscape — and arguably the most significant Daubert ruling in pharmaceutical mass tort litigation this decade — came when Judge Marston ruled that subjective symptoms alone are no longer sufficient to support a gastroparesis claim. Confirmed in 2026, the ruling requires all gastroparesis plaintiffs to demonstrate that their diagnosis was grounded in a properly performed gastric emptying study, specifically gastric scintigraphy, the gold-standard nuclear medicine imaging test for measuring how quickly food moves through the stomach.
This ruling has sweeping consequences. Patients who received informal or symptom-based gastroparesis diagnoses from their treating physicians — without undergoing the specific nuclear imaging test — may find their claims subject to dismissal unless they can obtain retroactive testing or additional medical records. The ruling aligns with Federal Rule of Evidence 702, which governs the admissibility of expert testimony and requires that opinions be based on sufficient facts or data and reliable methodology. The Daubert standard, derived from that rule, gives federal judges authority to act as gatekeepers — and Judge Marston exercised that authority decisively here.
For plaintiffs who do have properly documented gastric emptying studies showing delayed motility, the ruling may actually strengthen their claims by weeding out weaker cases and keeping expert testimony focused on objective, scientifically validated evidence.
Science Day for the NAION MDL: Vision Loss Claims Gain Scientific Momentum
On June 2, 2026, MDL 3163 — the vision-loss MDL — held its Science Day before Judge Marston. Science Days are informal presentations during which both sides’ scientific experts explain the underlying medical and scientific concepts to the judge, helping her evaluate future Daubert motions and expert challenges. The NAION MDL’s Science Day arrives at a moment of significant evidentiary momentum for plaintiffs.
A landmark study published in JAMA Ophthalmology in February 2026, analyzing data from more than 100,000 veterans, found that patients taking semaglutide had a 2.33-fold increased risk of NAION compared to patients on other diabetes medications, with a p-value below .001 — a threshold that indicates an extremely low probability that the association is due to chance. That statistical finding now sits at the center of MDL 3163’s general causation debate, and it will almost certainly be the focus of expert testimony and judicial scrutiny as the court evaluates whether plaintiffs can meet the legal standard for proving that GLP-1 drugs cause clinically significant vision damage.
NAION is a sudden and often permanent loss of vision caused by reduced blood flow to the optic nerve. Unlike gastroparesis — which is recoverable in some patients — NAION-related vision loss is typically irreversible, which may translate to substantially higher damages in any cases that reach trial.
FDA Label Changes and Regulatory Timeline in the Ozempic Lawsuit 2026
Regulatory actions by the FDA form a critical piece of the evidentiary record in any pharmaceutical mass tort, and the Ozempic lawsuit 2026 has seen two significant label updates in rapid succession. In January 2025, the FDA required Novo Nordisk to update the Ozempic label to state that the drug is “not recommended in patients with severe gastroparesis.” That warning — while protective for future patients — represents an acknowledgment by regulators that the gastroparesis risk is real and clinically significant.
Then, in October 2025, a second label revision added intestinal obstruction and severe constipation to the drug’s postmarketing experience section, expanding the official list of documented adverse events. Plaintiffs’ attorneys have argued that both label updates came years too late for patients who were already harmed. Under failure-to-warn doctrine, a drug manufacturer can be held liable when it knew or should have known about a drug’s risks but failed to adequately communicate them to prescribers and patients in a timely manner. These sequential FDA label revisions may provide plaintiffs with strong documentary evidence that Novo Nordisk possessed adverse event data long before it updated its warnings.
Bellwether Trials, Parallel State Litigation, and the Road to Resolution
As of June 2026, no global settlements have been announced in either MDL 3094 or MDL 3163. This is not unusual at this stage — most major pharmaceutical mass torts do not reach global settlement until after one or more bellwether trials establish the litigation’s value and risk profile for defendants. Bellwether trials in the Ozempic lawsuit 2026 are expected to begin in late 2026 to early 2027, according to docket tracking from MDLUpdate.com and LexGenius.
Outside the federal MDL structure, parallel state court litigation is actively proceeding in New Jersey — where Novo Nordisk maintains its U.S. headquarters — and in Indiana, where Eli Lilly is based. State courts operate under different procedural rules and may move on different timelines than the federal MDL, creating additional pressure on both defendants to consider resolution strategies. Individuals who lost a family member to complications allegedly related to GLP-1 drugs may also want to consult a wrongful death calculator to understand the range of damages that may be recoverable in a mass tort context.
The coming bellwether trials will be watched closely across the legal and pharmaceutical industries. A plaintiff verdict — particularly one with a substantial punitive damages award — could accelerate settlement negotiations dramatically. A defense verdict, conversely, might embolden Novo Nordisk and Eli Lilly to litigate individual claims more aggressively. Either outcome will reshape the Ozempic lawsuit 2026 calculus for the thousands of plaintiffs still waiting for their day in court. Those interested in understanding how mass tort settlement values are typically structured can explore a personal injury settlement calculator to see how factors like medical expenses, lost wages, and pain and suffering interact in large-scale litigation.
Frequently Asked Questions About the Ozempic Lawsuit 2026
How many Ozempic lawsuits are pending in 2026?
As of June 1, 2026, there are 3,763 pending cases in MDL 3094 (In re GLP-1 RAs Products Liability Litigation) in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. This represents a 130% increase since January 2025. A separate MDL — MDL 3163 — handles NAION vision-loss claims and is also assigned to Judge Marston in the same district.
What injuries qualify for the Ozempic lawsuit in 2026?
The primary injuries alleged in the Ozempic lawsuit 2026 include gastroparesis (approximately 75% of complaints), ileus or intestinal obstruction (approximately 18%), gallbladder complications (approximately 8%), and NAION-related vision loss, which is handled in a separate MDL. However, following Judge Marston’s Daubert ruling, gastroparesis claims must be supported by a properly performed gastric emptying study (scintigraphy) — subjective symptoms alone are no longer legally sufficient to support a gastroparesis diagnosis in this litigation.
Has there been any Ozempic lawsuit settlement in 2026?
No. As of June 2026, no global settlements have been announced by either Novo Nordisk or Eli Lilly in either MDL 3094 or MDL 3163. The litigation is still in its pre-trial phase, with bellwether trials expected in late 2026 to early 2027. Global settlement negotiations in pharmaceutical mass torts typically intensify after bellwether trial verdicts establish a clearer picture of liability and damages.
What is the NAION vision-loss MDL and how is it different from MDL 3094?
MDL 3163 is a separate federal multidistrict litigation created in December 2025 specifically for plaintiffs who allege that GLP-1 drugs — including Ozempic and Wegovy — caused NAION, a form of sudden and often permanent vision loss caused by reduced blood flow to the optic nerve. Unlike MDL 3094, which focuses on gastrointestinal injuries, MDL 3163 centers on neurological and ophthalmological harm. A February 2026 study published in JAMA Ophthalmology found a 2.33-fold increased NAION risk in semaglutide users compared to patients on other diabetes medications, providing significant scientific support for plaintiffs’ causation theories. Science Day for MDL 3163 was held on June 2, 2026.
Who can file an Ozempic lawsuit in 2026?
Individuals who took Ozempic, Wegovy, Rybelsus, Saxenda (Novo Nordisk), Mounjaro, Zepbound, or Trulicity (Eli Lilly) and subsequently developed gastroparesis with a proper gastric emptying study diagnosis, ileus, gallbladder complications, or NAION vision loss may have grounds to file a claim in the Ozempic lawsuit 2026. Cases may be filed in the federal MDL in the Eastern District of Pennsylvania or in state courts in New Jersey or Indiana. Prospective plaintiffs should gather all medical records, prescription history, and diagnostic test results — particularly gastric emptying studies — before consulting with a qualified mass tort attorney.
This content is provided for informational purposes only and does not constitute legal advice, create an attorney-client relationship, or substitute for consultation with a licensed attorney qualified in your jurisdiction.
Related reading: medical malpractice calculator
Related reading: medical malpractice calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.